Medisch Spectrum Twente is een Nederlands ziekenhuis met de hoofdvestiging in Enschede. De organisatie behoort tot de grootste niet-academische ziekenhuizen van Nederland. Het verzorgingsgebied telt circa 264.000 inwoners. Er is een erkenning die voorziet in het exploiteren van 1070 bedden.

During the past decade, Medisch Spectrum Twente conducted 123 clinical trials. In the 10-year time frame, 123 clinical trials started and 19 clinical trials were completed, i.e. on average, 15.4% percent of trials that started reached the finish line to date. In the past 5 years, 61 clinical trials started and 10 clinical trials were completed. i.e. 16.4% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Medisch Spectrum Twente" #1 sponsor was "European Organisation for Research and Treatment of Cancer - EORTC" with 14 trials, followed by "Radboud University Medical Center" with 13 trials sponsored, "Erasmus Medical Center" with 11 trials sponsored, "Stichting Hemato-Oncologie voor Volwassenen Nederland" with 10 trials sponsored and "University Medical Center Groningen" with 10 trials sponsored. Other sponsors include 142 different institutions and companies that sponsored additional 85 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Medisch Spectrum Twente" #1 collaborator was "ZonMw: The Netherlands Organisation for Health Research and Development" with 13 trials as a collaborator, "Medisch Spectrum Twente" with 8 trials as a collaborator, "Erasmus Medical Center" with 7 trials as a collaborator, "Dutch Cancer Society" with 6 trials as a collaborator and "Leiden University Medical Center" with 6 trials as a collaborator. Other collaborators include 193 different institutions and companies that were collaborators in the rest 158 trials.

According to Clinical.Site data, the most researched conditions in "Medisch Spectrum Twente" are "Atrial Fibrillation" (11 trials), "Coronary Artery Disease" (10 trials), "Lymphoma" (8 trials), "Colorectal Cancer" (6 trials) and "Heart Failure" (6 trials). Many other conditions were trialed in "Medisch Spectrum Twente" in a lesser frequency.

Most popular intervention types in "Medisch Spectrum Twente" are "Drug" (99 trials), "Device" (39 trials), "Procedure" (33 trials), "Other" (31 trials) and "Radiation" (15 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (19 trials), "radiation therapy" (9 trials), "doxorubicin hydrochloride" (7 trials), "cisplatin" (6 trials) and "cyclophosphamide" (5 trials). Other intervention names were less common.

The vast majority of trials in "Medisch Spectrum Twente" are 180 trials for "All" genders, 21 trials for "Female" genders and 3 trials for "Male" genders.

Currently, there are 87 active trials in "Medisch Spectrum Twente". 4 are not yet recruiting, 47 are recruiting, 33 are Active, not recruiting, and 3 are Enrolling by invitation. In total, there were 70 completed trials in Medisch Spectrum Twente, 1 suspended trials, and 21 terminated clinical trials to date.

Out of the total trials that were conducted in Medisch Spectrum Twente, 3 "Phase 1" clinical trials were conducted, 27 "Phase 2" clinical trials and 63 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 16 trials, and there were also 54 trials that are defined as “Not Applicable".